XML 49 R42.htm IDEA: XBRL DOCUMENT
v3.26.1

Licensing Activities and Business Development - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Apr. 30, 2026 | Sep. 30, 2025 | Jun. 30, 2025 | May 31, 2025 | Jan. 31, 2025 | Oct. 31, 2023 | May 31, 2021 | Mar. 31, 2021 | Sep. 30, 2019 | Mar. 31, 2023 | Jun. 30, 2026 | Dec. 31, 2024 | Dec. 29, 2022
License and Stock Purchase Agreement [Member] | AbbVie [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non refundable upfront fee |  |  |  |  |  |  |  |  | $ 0.6 |  |  |  |
License Agreement [Member] | AbbVie [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  |  |  | $ 0.0 |  |
Milestone payments |  |  |  |  | $ 3.0 |  |  |  |  |  |  |  |
License Agreement [Member] | Roche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued |  |  |  |  |  |  |  |  |  |  |  |  | 482,313
Future milestone payment |  |  |  |  |  |  |  |  |  |  | 0.0 |  |
Non-refundable upfront payment |  |  |  |  |  |  | $ 4.0 | $ 0.5 |  |  |  |  |
License Agreement [Member] | Mabwell [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  |  |  | 0.0 |  |
Upfront payment |  |  |  |  |  |  |  |  |  | $ 10.0 |  |  |
License Agreement [Member] | OBB [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  |  | $ 0.2 |
Future milestone recievable |  |  |  |  |  |  |  |  |  |  | 0.0 |  |
License Agreement [Member] | OBB [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future consideration recievable on clinical |  |  |  |  |  |  |  |  |  |  |  | 7.0 |
Future consideration recievable on regulatory |  |  |  |  |  |  |  |  |  |  |  | 35.0 |
Future consideration recievable on sales milestones |  |  |  |  |  |  |  |  |  |  |  | $ 160.0 |
Merger Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone recievable |  |  |  |  |  |  |  |  |  |  | 0.0 |  |
Contingent and sales-based milestone payments |  |  |  | $ 50.0 |  |  |  |  |  |  |  |  |
Upfront cash payment |  |  |  | 0.0 |  |  |  |  |  |  |  |  |
Development and Regulatory Milestone First Indication [Member] | License Agreement [Member] | Roche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  | 50.0 |  |  |  |  |  |
Development and Regulatory Milestone Second Indication [Member] | License Agreement [Member] | Roche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  | 35.0 |  |  |  |  |  |
Development and Regulatory First Indication First Milestone [Member] | License Agreement [Member] | Roche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  | $ 10.0 |  |  |  |  |  |  |  |  |  |
Development and Regulatory First Indication First Milestone [Member] | License Agreement [Member] | Mabwell [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 5.0 |  |  |  |  |  |  |
Development and Regulatory First Indication Second Milestone [Member] | License Agreement [Member] | Roche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  |  |  | $ 15.0 |  |
Development and Regulatory First Indication Second Milestone [Member] | License Agreement [Member] | Mabwell [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  | $ 10.0 |  |  |  |  |  |  |  |  |  |  |
Development and Regulatory Second Indication First Milestone [Member] | License Agreement [Member] | Mabwell [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments | $ 5.0 |  |  |  |  |  |  |  |  |  |  |  |
Development and Regulatory [Member] | License Agreement [Member] | Mabwell [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  |  | 127.5 |  |  |
Development [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  | 18.0 |  |  |  |
Development [Member] | Merger Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  | 5.6 |  |  |  |  |  |  |  |  |
Commercialization [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  | 45.0 |  |  |  |
Sales-based [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  | $ 87.5 |  |  |  |
Sales-based [Member] | License Agreement [Member] | Roche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  | $ 120.0 |  |  |  |  |  |
Sales-based [Member] | License Agreement [Member] | Mabwell [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  |  |  |  |  |  |  | $ 275.0 |  |  |
Sales-based [Member] | Merger Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payment |  |  |  | $ 20.0 |  |  |  |  |  |  |  |  |

X
- Definition Amount of upfront payment received. + References No definition available. + Details
Name: | iron_AmountOfUpfrontPaymentReceived
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination contingent consideration sales based milestone payments. + References No definition available. + Details
Name: | iron_BusinessCombinationContingentConsiderationSalesBasedMilestonePayments
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Future consideration recievable on clinical. + References No definition available. + Details
Name: | iron_FutureConsiderationRecievableOnClinical
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Future consideration recievable on regulatory. + References No definition available. + Details
Name: | iron_FutureConsiderationRecievableOnRegulatory
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Future consideration recievable on sales milestones. + References No definition available. + Details
Name: | iron_FutureConsiderationRecievableOnSalesMilestones
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Future milestone payment. + References No definition available. + Details
Name: | iron_FutureMilestonePayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future milestone recievable. + References No definition available. + Details
Name: | iron_FutureMilestoneRecievable
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | iron_MilestonePayments
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable upfront fee. + References No definition available. + Details
Name: | iron_NonRefundableUpfrontFee
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | iron_UpfrontCashPayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront non-refundable payment. + References No definition available. + Details
Name: | iron_UpfrontNonRefundablePayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | iron_UpfrontPayment
Namespace Prefix: | iron_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=iron_LicenseAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_AbbvieDeutschlandGmbhCoKgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=iron_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_MabwellTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_OakBayBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=iron_MergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryFirstIndicationFirstMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryFirstIndicationSecondMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatorySecondIndicationFirstMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_CommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=iron_Sales-BasedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |